Vxrt stock price forecast narratives in financial media point to

vxrt stock price forecast narratives in financial media point to macro headwinds such as interest rate policy, which can compress valuations for growth-oriented biotech firms. We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here . The latest vxrt stock price forecast suggests short-term volatility as the biotech sector reacts to recent FDA updates, with technical indicators showing support near $0.80 and potential resistance at $1.